CD70 CAR-T cell therapy (Chongqing Precision Biotech)

CD70 CAR-T 细胞疗法（重庆精准生物技术）

Report date: 2024/01/29 15:08:51

Base Information

Drug NameCD70 CAR-T cell therapy (Chongqing Precision Biotech)
Drug Alias NameAnti-CD70 chimeric antigen receptor T cell therapy (Chongqing Precision Biotech)CD70-targeted CAR-T (Chongqing Precision Biotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD70
TargetsCD70 antigen
Therapy Area/IndicationsSolid tumoursScleroderma, SystemicDermatomyositis +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChongqing Precision Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChongqing Precision Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursScleroderma, SystemicDermatomyositis +[13] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A